



NEWS RELEASE

FOR IMMEDIATE RELEASE

Contacts:

Sharon Lewis
XDx, Inc.
415-287-2300

XDx to Present at the Third Annual JMP Securities Healthcare Focus Conference

Company to Highlight Recent FDA Clearance of AlloMap® Test

BRISBANE, Calif., October 6, 2008 – XDx, a molecular diagnostics company, today announced that Pierre Cassigneul, president and chief executive officer, is scheduled to present at the Third Annual JMP Securities Healthcare Focus Conference on Monday, October 6, 2008 at 2:20 p.m. (ET) at the Le Parker Meridien in New York City.

XDx recently announced that it received market clearance from the U.S. Food and Drug Administration (FDA) for AlloMap® Molecular Expression Testing. The AlloMap Test is a noninvasive, multi-gene molecular diagnostics blood test used to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing, in conjunction with standard clinical assessment. XDx is the first U.S. molecular diagnostics company to obtain FDA clearance of an In Vitro Diagnostic Multivariate Index Assay (IVDMIA) for use in transplant management, and Mr. Cassigneul will provide further information regarding AlloMap during his presentation.

About XDx

Based in Brisbane, California, XDx is a molecular diagnostics company focused on the discovery, development and commercialization of noninvasive gene expression-based tests for the monitoring of transplant rejection and autoimmune diseases. The company has developed a proprietary new method for noninvasively monitoring immune system activity by measuring gene expression in a patient's peripheral blood. This work is the basis for AlloMap Molecular Expression Testing, which provides transplant physicians with a new tool to aid in the identification of the probability of acute cellular rejection for postcardiac transplant patient management.

Some of the AlloMap Molecular Expression Technology developed and implemented by XDx in heart transplant patient management may be applicable to other diseases that involve transplant rejection and the immune system. XDx's noninvasive technology offers the potential to decrease healthcare costs and significantly improve the quality of life for patients with a variety of life-threatening or life-altering immune-mediated diseases.

###